Why AngioDynamics Inventory Is Sinking Right now

• The medical know-how firm introduced the retirement of CEO Jim Clemmer.

• This information creates uncertainty for AngioDynamics — and traders dislike uncertainty.

• Nevertheless, the corporate’s enterprise seems to be bettering.

• 10 shares we like higher than AngioDynamics ›

Shares of AngioDynamics (NASDAQ: ANGO) had been sinking 13.1% as of 11:02 a.m. ET. The sell-off got here after the medical know-how firm introduced its third-quarter outcomes earlier than the market open.

These outcomes had been truly fairly good. AngioDynamics reported Q3 income of $79.4 million, up 8.8% year-over-year on a professional forma foundation and better than the consensus Wall Road estimate of $76.4 million. The corporate posted an adjusted lack of $59,000, which amounted to roughly $0.00 per share. Analysts anticipated an adjusted internet lack of $0.10 per share.

So why did this medical machine inventory unload so closely? Most likely as a result of AngioDynamics introduced the sudden retirement of CEO Jim Clemmer.

Clemmer has led AngioDynamics since 2016. In a press release launched within the firm’s Q3 press launch, he stated, “After ten years at AngioDynamics, I really feel prepared to maneuver on to the subsequent chapter of my life.”

His resolution to retire shocked traders – and, seemingly, AngioDynamics’ board of administrators as properly. The board did not have a successor already lined up. As an alternative, it has shaped a search committee to “conduct a complete search” for the subsequent CEO, with help from an government search agency.

Traders dislike uncertainty. Clemmer’s departure creates uncertainty for AngioDynamics.

Nevertheless, Clemmer does not appear to be abandoning ship as a result of he is involved that it is sinking. He’ll proceed to steer the corporate till his alternative is discovered.

Additionally, apart from the information about Clemmer, issues look like wanting up for AngioDynamics. The corporate elevated its internet gross sales and adjusted EBITDA steerage for fiscal 12 months 2026. It just lately obtained U.S. Meals and Drug Administration (FDA) clearance for a modified AlphaVac F1885 System and two FDA Investigational Gadget Exemption (IDE) approvals.

Ought to traders purchase this inventory on the dip? I feel the sell-off is overdone. Nevertheless, different shares provide extra engaging risk-reward propositions, for my part.

Before you purchase inventory in AngioDynamics, take into account this:

The Motley Idiot Inventory Advisor analyst staff simply recognized what they imagine are the 10 greatest shares for traders to purchase now… and AngioDynamics wasn’t considered one of them. The ten shares that made the reduce might produce monster returns within the coming years.

Think about when Netflix made this record on December 17, 2004… in case you invested $1,000 on the time of our suggestion, you’d have $493,290!* Or when Nvidia made this record on April 15, 2005… in case you invested $1,000 on the time of our suggestion, you’d have $1,153,214!*

Now, it’s value noting Inventory Advisor’s whole common return is 973% — a market-crushing outperformance in comparison with 195% for the S&P 500. Do not miss the most recent high 10 record, accessible with Inventory Advisor, and be part of an investing neighborhood constructed by particular person traders for particular person traders.

See the ten shares »

*Inventory Advisor returns as of January 6, 2026.

Keith Speights has no place in any of the shares talked about. The Motley Idiot has no place in any of the shares talked about. The Motley Idiot has a disclosure coverage.

Why AngioDynamics Inventory Is Sinking Right now was initially printed by The Motley Idiot